Overview Dividends

(BHC) Bausch Health Companies - Ratings and Ratios

Exchange: NYSE • Country: Canada • Currency: USD • Type: Common Stock • ISIN: CA0717341071

Gastroenterology, Dermatology, Neurology, Ophthalmology, Aesthetics

BHC EPS (Earnings per Share)

EPS Growth (3Y CAGR): 4.54%
EPS Trend (3Y Correlation): 2.1%

BHC Revenue

Revenue Growth (3Y CAGR): -27.32%
Revenue Trend (3Y Correlation): -27.5%

Risk via 10d forecast
Volatility	61.3%
Value at Risk 5%th	83.1%
Relative Tail Risk	-17.56%

Reward TTM
Sharpe Ratio	-0.43
Alpha	-41.76

Character TTM
Hurst Exponent	0.582
Beta	0.856
Beta Downside	1.647

Drawdowns 3y
Max DD	59.28%
Mean DD	26.66%
Median DD	26.09%

Description: BHC Bausch Health Companies November 11, 2025

Bausch Health Companies Inc. (NYSE:BHC) is a diversified specialty pharma and medical-device firm headquartered in Laval, Canada. It markets products across gastroenterology, hepatology, neurology, dermatology, generic and OTC medicines, aesthetic devices, and eye-care solutions. The business is organized into five segments: Salix (GI therapies), International (branded, generic, OTC, and aesthetic devices outside North America), Solta Medical (aesthetic devices), Diversified (neurology, dermatology, generics, dentistry), and Bausch + Lomb (vision-care, surgical and ophthalmic pharmaceuticals).

As of FY 2023, BHC generated roughly $2.5 billion in revenue, with an adjusted EBITDA margin near 15 % and net debt of about $5.3 billion, reflecting its capital-intensive acquisition strategy. Key economic drivers include an aging global population that fuels demand for chronic-disease treatments (especially GI and eye-care), continued growth in the OTC self-care market, and pricing pressure from generic competition. The company’s pipeline features several late-stage generic GI products and new ophthalmic formulations, which could improve margin expansion if successfully launched.

For a deeper quantitative assessment, you may find ValueRay’s detailed valuation model for BHC worth reviewing.

BHC Stock Overview

Market Cap in USD	2,564m
Sub-Industry	Pharmaceuticals
IPO / Inception	1994-03-29
Return 12m vs S&P 500	-36.2%
Analyst Rating	3.0 of 5

BHC Dividends

Currently no dividends paid

BHC Growth Ratios

CAGR 3y	-4.09%
CAGR/Max DD Calmar Ratio	-0.07
CAGR/Mean DD Pain Ratio	-0.15
Current Volume	1734.9k
Average Volume	2255k

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (362.0m TTM) > 0 and > 6% of Revenue (6% = 495.6m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA 0.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 17.61% (prev 8.92%; Δ 8.69pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.06 (>3.0%) and CFO 1.51b > Net Income 362.0m (YES >=105%, WARN >=100%)

Net Debt (19.68b) to EBITDA (4.79b) ratio: 4.11 <= 3.0 (WARN <= 3.5)

Current Ratio 1.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (373.1m) change vs 12m ago 1.28% (target <= -2.0% for YES)

Gross Margin 81.55% (prev 70.87%; Δ 10.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 30.97% (prev 35.70%; Δ -4.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.14 (EBITDA TTM 4.79b / Interest Expense TTM 3.13b) >= 6 (WARN >= 3)

Altman Z'' 0.06

(A) 0.05 = (Total Current Assets 6.24b - Total Current Liabilities 4.79b) / Total Assets 26.80b

(B) -0.36 = Retained Earnings (Balance) -9.55b / Total Assets 26.80b

(D) -0.03 = Book Value of Equity -839.2m / Total Liabilities 26.44b

Total Rating: 0.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 51.69

1. Piotroski 2.50pt = -2.50

2. FCF Yield 4.92% = 2.46

3. FCF Margin 13.24% = 3.31

4. Debt/Equity -37.24 = -2.50

5. Debt/Ebitda 4.11 = -2.50

6. ROIC - WACC (= 6.30)% = 7.88

7. RoE -38.20% = -2.50

8. Rev. Trend -27.52% = -2.06

9. EPS Trend 2.07% = 0.10

What is the price of BHC shares?

As of November 18, 2025, the stock is trading at USD 6.13 with a total of 1,734,906 shares traded.
Over the past week, the price has changed by -4.22%, over one month by +1.32%, over three months by -23.57% and over the past year by -26.85%.

Is Bausch Health Companies a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Bausch Health Companies is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 51.69 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BHC is around 5.26 USD . This means that BHC is currently overvalued and has a potential downside of -14.19%.

Is BHC a buy, sell or hold?

Bausch Health Companies has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold BHC.

Strong Buy: 0
Buy: 1
Hold: 5
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the BHC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	7.2	17%
Analysts Target Price	7.2	17%
ValueRay Target Price	5.8	-4.7%

BHC Fundamental Data Overview November 17, 2025

Market Cap USD = 2.56b (2.56b USD * 1.0 USD.USD)
P/E Trailing = 6.4742
P/E Forward = 1.4758
P/S = 0.2557
P/B = 18.7773
P/EG = 0.6315
Beta = 0.397
Revenue TTM = 8.26b USD
EBIT TTM = 3.57b USD
EBITDA TTM = 4.79b USD
Long Term Debt = 20.46b USD (from longTermDebt, last quarter)
Short Term Debt = 578.4m USD (from shortTermDebt, last quarter)
Debt = 21.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.68b USD (from netDebt column, last quarter)
Enterprise Value = 22.25b USD (2.56b + Debt 21.02b - CCE 1.34b)
Interest Coverage Ratio = 1.14 (Ebit TTM 3.57b / Interest Expense TTM 3.13b)
FCF Yield = 4.92% (FCF TTM 1.09b / Enterprise Value 22.25b)
FCF Margin = 13.24% (FCF TTM 1.09b / Revenue TTM 8.26b)
Net Margin = 4.38% (Net Income TTM 362.0m / Revenue TTM 8.26b)
Gross Margin = 81.55% ((Revenue TTM 8.26b - Cost of Revenue TTM 1.52b) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 69.80%)
Tobins Q-Ratio = 0.83 (Enterprise Value 22.25b / Total Assets 26.80b)
Interest Expense / Debt = 9.52% (Interest Expense 2.00b / Debt 21.02b)
Taxrate = 17.89% (39.0m / 218.0m)
NOPAT = 2.93b (EBIT 3.57b * (1 - 17.89%))
Current Ratio = 1.30 (Total Current Assets 6.24b / Total Current Liabilities 4.79b)
Debt / Equity = -37.24 (negative equity) (Debt 21.02b / totalStockholderEquity, last quarter -564.4m)
Debt / EBITDA = 4.11 (Net Debt 19.68b / EBITDA 4.79b)
Debt / FCF = 17.99 (Net Debt 19.68b / FCF TTM 1.09b)
Total Stockholder Equity = -947.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.35% (Net Income 362.0m / Total Assets 26.80b)
RoE = -38.20% (negative equity) (Net Income TTM 362.0m / Total Stockholder Equity -947.6m)
RoCE = 18.28% (EBIT 3.57b / Capital Employed (Equity -947.6m + L.T.Debt 20.46b))
RoIC = 14.27% (NOPAT 2.93b / Invested Capital 20.53b)
WACC = 7.97% (E(2.56b)/V(23.59b) * Re(9.17%) + D(21.02b)/V(23.59b) * Rd(9.52%) * (1-Tc(0.18)))
Discount Rate = 9.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.07%
[DCF Debug] Terminal Value 65.53% ; FCFE base≈1.06b ; Y1≈696.5m ; Y5≈318.5m
Fair Price DCF = 14.12 (DCF Value 5.23b / Shares Outstanding 370.5m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 2.07 | EPS CAGR: 4.54% | SUE: 0.38 | # QB: 0
Revenue Correlation: -27.52 | Revenue CAGR: -27.32% | SUE: -4.0 | # QB: 0

Additional Sources for BHC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle